社区获得性肺炎的预防、管理及治疗进展
Advances in the prevention, management, and treatment of community-acquired pneumonia.
作者信息
Pletz Mathias W, Welte Tobias, Ott Sebastian R
出版信息
F1000 Med Rep. 2010 Jul 22;2:53. doi: 10.3410/M2-53.
Abstract
Despite the availability of powerful antibiotics, community-acquired pneumonia (CAP) remains one of the leading reasons for morbidity and mortality worldwide, and despite the availability of powerful antibiotics, there has been only little improvement in case fatality rates for many years. Consequently, it cannot be expected that novel antibiotics will substantially improve outcomes in CAP. Therefore, this review focuses on novel approaches that may reduce CAP-related mortality: the impact of immunomodulation by macrolides and fluoroquinolones and the prevention of CAP by pneumococcal vaccines.
摘要
尽管有强效抗生素，但社区获得性肺炎（CAP）仍是全球发病和死亡的主要原因之一，而且尽管有强效抗生素，多年来病死率几乎没有改善。因此，不能期望新型抗生素能显著改善CAP的治疗结果。因此，本综述重点关注可能降低CAP相关死亡率的新方法：大环内酯类和氟喹诺酮类药物的免疫调节作用以及肺炎球菌疫苗预防CAP的作用。
相似文献
1
Advances in the prevention, management, and treatment of community-acquired pneumonia.社区获得性肺炎的预防、管理及治疗进展
F1000 Med Rep. 2010 Jul 22;2:53. doi: 10.3410/M2-53.
2
The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.住院社区获得性肺炎治疗中联合治疗与单一疗法的争议。
Chest. 2005 Aug;128(2):940-6. doi: 10.1378/chest.128.2.940.
3
Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis.韩国成年人社区获得性肺炎和肺炎球菌病的发病率和病死率：基于人群的集水区分析。
PLoS One. 2018 Mar 29;13(3):e0194598. doi: 10.1371/journal.pone.0194598. eCollection 2018.
4
Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.大环内酯类抗生素在社区获得性肺炎中的联合应用效果最新进展
Respir Investig. 2015 Sep;53(5):201-9. doi: 10.1016/j.resinv.2015.05.003. Epub 2015 Aug 13.
5
Current treatment of community-acquired pneumonia.社区获得性肺炎的当前治疗。
Expert Opin Pharmacother. 2013 Jul;14(10):1319-32. doi: 10.1517/14656566.2013.798647. Epub 2013 May 10.
6
An update on community-acquired pneumonia in adults.
Compr Ther. 2000 Winter;26(4):283-93. doi: 10.1007/s12019-000-0031-8.
7
Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.肺炎链球菌所致社区获得性肺炎的严重程度评分：5年经验
Int J Antimicrob Agents. 2004 Nov;24(5):485-90. doi: 10.1016/j.ijantimicag.2004.05.006.
8
The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.肺炎链球菌引起的社区获得性肺炎中对大环内酯类药物耐药性升高的比较性研究进展
Drug Des Devel Ther. 2014 Oct 3;8:1733-43. doi: 10.2147/DDDT.S71349. eCollection 2014.
9
The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.大环内酯类药物和β-内酰胺类药物的给药顺序可能会影响社区获得性肺炎住院患者的结局：来自社区获得性肺炎组织的研究结果。
Infect Dis (Lond). 2018 Jan;50(1):13-20. doi: 10.1080/23744235.2017.1350881. Epub 2017 Jul 12.
10
New trends in the prevention and management of community-acquired pneumonia.社区获得性肺炎预防与管理的新趋势
Neth J Med. 2012 Oct;70(8):337-48.
引用本文的文献
1
Illness representations on pneumonia and pneumococcal vaccination uptake among community-living Chinese people with high-risk conditions aged ≥65 years --- a population-based study.≥65岁有高危状况的社区居住中国人群中肺炎及肺炎球菌疫苗接种的疾病认知——一项基于人群的研究
Hum Vaccin Immunother. 2021 May 4;17(5):1455-1462. doi: 10.1080/21645515.2020.1814653. Epub 2020 Sep 29.
2
International pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance.国际肺炎球菌克隆尽管积累了抗生素耐药性，但与其他菌株的适应性相当或超过了其他菌株。
Antimicrob Agents Chemother. 2011 Oct;55(10):4915-7. doi: 10.1128/AAC.00250-11. Epub 2011 Aug 8.
本文引用的文献
1
2
Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.糖皮质激素治疗社区获得性肺炎的疗效：一项随机双盲临床试验。
Am J Respir Crit Care Med. 2010 May 1;181(9):975-82. doi: 10.1164/rccm.200905-0808OC. Epub 2010 Feb 4.
3
Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades.70 余年来侵袭性肺炎球菌病和肺炎球菌血清型的时间趋势。
Clin Infect Dis. 2010 Feb 1;50(3):329-37. doi: 10.1086/649872.
4
Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes.肺炎链球菌性肺炎合并感染性休克：宿主和病原体相关因素及预后。
Thorax. 2010 Jan;65(1):77-81. doi: 10.1136/thx.2009.123612. Epub 2009 Dec 8.
5
Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.阿奇霉素和克拉霉素主要通过影响巨噬细胞衍生的粒细胞-巨噬细胞集落刺激因子和白细胞介素-1β来抑制脂多糖诱导的小鼠肺部中性粒细胞增多。
J Pharmacol Exp Ther. 2009 Oct;331(1):104-13. doi: 10.1124/jpet.109.155838. Epub 2009 Jul 24.
6
In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production.氟喹诺酮类药物对脂多糖诱导的促炎细胞因子产生的体内和体外作用。
J Infect Chemother. 2009 Jun;15(3):168-73. doi: 10.1007/s10156-009-0680-1. Epub 2009 Jun 25.
7
Statin use and risk of community acquired pneumonia in older people: population based case-control study.他汀类药物的使用与老年人社区获得性肺炎风险：基于人群的病例对照研究
BMJ. 2009 Jun 16;338:b2137. doi: 10.1136/bmj.b2137.
8
Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network.社区获得性肺炎的全球及局部流行病学：CAPNETZ网络的经验
Semin Respir Crit Care Med. 2009 Apr;30(2):127-35. doi: 10.1055/s-0029-1202941. Epub 2009 Mar 18.
9
Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.静脉注射β-内酰胺类/大环内酯类药物与β-内酰胺类单药治疗对社区获得性肺炎住院患者死亡率的影响。
J Antimicrob Chemother. 2009 May;63(5):1025-33. doi: 10.1093/jac/dkp088. Epub 2009 Mar 17.
10
Long-term macrolide therapy in chronic inflammatory airway diseases.慢性炎症性气道疾病的长期大环内酯类药物治疗
Eur Respir J. 2009 Jan;33(1):171-81. doi: 10.1183/09031936.00042208.
Zotero 插件